NO20050450L - Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft - Google Patents

Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft

Info

Publication number
NO20050450L
NO20050450L NO20050450A NO20050450A NO20050450L NO 20050450 L NO20050450 L NO 20050450L NO 20050450 A NO20050450 A NO 20050450A NO 20050450 A NO20050450 A NO 20050450A NO 20050450 L NO20050450 L NO 20050450L
Authority
NO
Norway
Prior art keywords
combination
cancer
radiotherapy
inhibitor
treatment
Prior art date
Application number
NO20050450A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218525A external-priority patent/GB0218525D0/en
Priority claimed from GB0307560A external-priority patent/GB0307560D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20050450L publication Critical patent/NO20050450L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20050450A 2002-08-09 2005-01-26 Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft NO20050450L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0218525A GB0218525D0 (en) 2002-08-09 2002-08-09 Combination therapy
GB0307560A GB0307560D0 (en) 2003-04-02 2003-04-02 Combination therapy
PCT/GB2003/003388 WO2004014383A1 (en) 2002-08-09 2003-08-05 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer

Publications (1)

Publication Number Publication Date
NO20050450L true NO20050450L (no) 2005-05-02

Family

ID=31716921

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050450A NO20050450L (no) 2002-08-09 2005-01-26 Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft

Country Status (13)

Country Link
US (1) US20050222183A1 (es)
EP (1) EP1534287A1 (es)
JP (1) JP2006502132A (es)
KR (1) KR20050056190A (es)
CN (1) CN1313094C (es)
AU (1) AU2003249000B2 (es)
BR (1) BR0313116A (es)
CA (1) CA2495487A1 (es)
IL (1) IL166522A0 (es)
MX (1) MXPA05001458A (es)
NO (1) NO20050450L (es)
NZ (1) NZ537753A (es)
WO (1) WO2004014383A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7160889B2 (en) * 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
UA81619C2 (ru) * 2002-02-01 2008-01-25 Астразенека Аб Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR101089462B1 (ko) 2002-11-04 2011-12-07 아스트라제네카 아베 Ｓｒｃ 티로신 키나제 억제제로서의 퀴나졸린 유도체
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
KR20120093411A (ko) * 2003-07-10 2012-08-22 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
JP4945133B2 (ja) * 2006-01-19 2012-06-06 富士フイルムＲｉファーマ株式会社 ４−フェノキシキナゾリン誘導体放射性化合物
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
CN106317022A (zh) * 2015-06-25 2017-01-11 中美华世通生物医药科技（武汉）有限公司 化合物的制备方法和用途
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306306T3 (es) * 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.

Also Published As

Publication number Publication date
CA2495487A1 (en) 2004-02-19
IL166522A0 (en) 2006-01-15
KR20050056190A (ko) 2005-06-14
CN1313094C (zh) 2007-05-02
WO2004014383A1 (en) 2004-02-19
BR0313116A (pt) 2005-07-05
NZ537753A (en) 2008-04-30
US20050222183A1 (en) 2005-10-06
CN1674905A (zh) 2005-09-28
AU2003249000B2 (en) 2007-04-05
EP1534287A1 (en) 2005-06-01
MXPA05001458A (es) 2005-06-06
AU2003249000A1 (en) 2004-02-25
JP2006502132A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
CY1111565T1 (el) Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
CY1106259T1 (el) Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
ATE500832T1 (de) Kombination von zd6474 und pemetrexed
DE602004011051D1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
NO20064753L (no) Kombinasjonsterapi
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.
GB0223379D0 (en) Combination therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application